Apremilast: all 117 studies that test it

Page 1 of 2. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.

• Apremilast Added to Antihistamines in Chronic UrticariaEnrolling by invitationNCT07850843Phase 2
• Methotrexate Versus Apremilast for Pruritus in PsoriasisNot yet recruitingNCT07432386Phase 4
• Apremilast and Adalimumab in Psoriatic Arthritis PatientsNot yet recruitingNCT07398651Not applicable
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care HospitalRecruitingNCT07337434Early Phase 1
• Human Laboratory Study of Apremilast for Alcohol Use DisorderRecruitingNCT07325266Phase 2
• Phase 2 Study of Apremilast in Women and Men With Alcohol Use DisorderRecruitingNCT07029529Phase 2
• A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisRecruitingNCT05767047Phase 3
• Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisRecruitingNCT04804553Phase 3
• Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingNCT04610476Phase 3
• Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's DiseaseRecruitingNCT04528082Phase 3
• Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous StomatitisRecruitingNCT04227314Phase 3
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingNCT02735707Phase 3
• Effects of Treatment With Biological Agents on Vascular and Cardiac Function in PsoriasisRecruitingNCT02144857Phase 4
• Apremilast for Erythema MultiformeCompletedNCT05875714Phase 2Results posted
• Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)CompletedNCT05174065Phase 3Results posted
• Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic TherapyCompletedNCT04908475Phase 4Results posted
• A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without FoodTerminatedNCT04811573Phase 1Results posted
• Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized PatientsCompletedNCT04590586Phase 3Results posted
• Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)CompletedNCT04572997Phase 2Results posted
• Apremilast 30 mg Twice Daily (BID) Combined With DupilumabCompletedNCT04306965Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar PustulosisCompletedNCT04057937Phase 2Results posted
• A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical TherapyCompletedNCT03930186Phase 3Results posted
• A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic ArthritisCompletedNCT03783026Phase 4Results posted
• An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital PsoriasisCompletedNCT03777436Phase 3Results posted
• A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of LifeCompletedNCT03774875Phase 4Results posted
• Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.CompletedNCT03747939Phase 4Results posted
• Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and EfficacyCompletedNCT03721172Phase 3Results posted
• Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisCompletedNCT03701763Phase 3Results posted
• Apremilast for RASCompletedNCT03690544Phase 4Results posted
• Evaluation of Add on Enstilar in Patients Using Otezla for PsoriasisCompletedNCT03587194Phase 4Results posted
• Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant DermatomyositisCompletedNCT03529955Phase 2Results posted
• Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)CompletedNCT03521687Phase 4Results posted
• Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With ApremilastCompletedNCT03442088Phase 2Results posted
• A Study Examining the Medication Apremilast as Treatment for Chronic ItchCompletedNCT03239106Phase 2Results posted
• Medication Development in Alcoholism: Apremilast Versus PlaceboCompletedNCT03175549Phase 2Results posted
• A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the ScalpCompletedNCT03123471Phase 3Results posted
• Vascular Inflammation in Psoriasis - ApremilastCompletedNCT03082729Phase 4Results posted
• A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail PsoriasisCompletedNCT03022617Phase 4Results posted
• Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical TherapyCompletedNCT03000309Phase 4Results posted
• Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean SubjectsCompletedNCT02802735Phase 1Results posted
• A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy AdultsCompletedNCT02777554Phase 1Results posted
• Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia AreataCompletedNCT02684123Not applicableResults posted
• Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral SuspensionCompletedNCT02641353Phase 1Results posted
• A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT02576678Phase 2Results posted
• A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.CompletedNCT02425826Phase 4Results posted
• Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque PsoriasisCompletedNCT02412644Phase 4Results posted
• Apremilast in Palmo-Plantar PsoriasisCompletedNCT02400749Phase 4Results posted
• A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's DiseaseCompletedNCT02307513Phase 3Results posted
• Efficacy and Safety Study of Apremilast to Treat Active Ulcerative ColitisCompletedNCT02289417Phase 2Results posted
• Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic DermatitisCompletedNCT02087943Phase 2Results posted
• Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type PsoriasisCompletedNCT01988103Phase 2Results posted
• Safety and Efficacy Study of Apremilast to Treat Psoriatic ArthritisCompletedNCT01925768Phase 3Results posted
• Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque PsoriasisCompletedNCT01690299Phase 3Results posted
• Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy AdultsCompletedNCT01634191Phase 1Results posted
• Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy AdultsCompletedNCT01634178Phase 1Results posted
• Study of Apremilast to Treat Subjects With Active Ankylosing SpondylitisCompletedNCT01583374Phase 3Results posted
• A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of ApremilastCompletedNCT01561963Phase 1Results posted
• Apremilast for Atopic Dermatitis - A Pilot Study in AdultsCompletedNCT01393158Phase 2Results posted
• Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)CompletedNCT01307423Phase 3Results posted
• Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid ArthritisTerminatedNCT01285310Phase 2Results posted
• Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.CompletedNCT01232283Phase 3Results posted
• PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic ArthritisCompletedNCT01212770Phase 3Results posted
• PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic ArthritisCompletedNCT01212757Phase 3Results posted
• Efficacy and Safety Study of Apremilast to Treat Active Psoriatic ArthritisCompletedNCT01172938Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With DermatomyositisTerminatedNCT01140503Not applicableResults posted
• Apremilast in the Treatment of Moderate to Severe AcneTerminatedNCT01074502Phase 2Results posted
• Open Label Pilot Study of Apremilast in Treatment of RosaceaCompletedNCT01045551Phase 2Results posted
• Spondylitis Trial of Apremilast for Better Rheumatic TherapyCompletedNCT00944658Phase 2Results posted
• Study of Apremilast in Atopic or Contact DermatitisCompletedNCT00931242Phase 2Results posted
• Apremilast in the Treatment of UveitisTerminatedNCT00889421Phase 1/2Results posted
• Safety and Efficacy of CC-10004 for Prurigo NodularisCompletedNCT00869089Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet DiseaseCompletedNCT00866359Phase 2Results posted
• CC-10004 For The Treatment Of VulvodyniaCompletedNCT00814632Phase 2Results posted
• Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)CompletedNCT00773734Phase 2Results posted
• Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus PatientsCompletedNCT00708916Phase 1/2Results posted
• An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain SyndromeCompletedNCT00701311Phase 2Results posted
• Apremilast Safety and PK Study in Recalcitrant Plaque PsoriasisCompletedNCT00521339Phase 2Results posted
• Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic ArthritisCompletedNCT00456092Phase 2Results posted
• Comparative Efficacy of Apremilast and Acitretin in Moderate-to-Severe Hidradenitis SuppurativaCompletedNCT07708480Phase 4
• Apremilast for Alcohol Use Disorder Treatment in Women and MenActive, not recruitingNCT06324435Phase 1
• Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen PlanusCompletedNCT06260904Phase 4
• A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)CompletedNCT06122649Phase 3
• A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque PsoriasisCompletedNCT06088199Phase 3
• Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human SubjectsCompletedNCT06084663Phase 3
• Efficacy and Safety of Apremilast in PsoriasisCompletedNCT06032858Phase 4
• Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi.CompletedNCT05926882Phase 4
• A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque PsoriasisCompletedNCT05565560Phase 3
• A Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum LeprosumCompletedNCT04822909Phase 4
• The Maintenance Effect of Enstilar Foam in Combination With OtezlaStatus unknownNCT04555707Phase 4
• Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP)Status unknownNCT04515732Phase 4
• I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingNCT04488081Phase 2
• A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisCompletedNCT04175613Phase 3
• Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne ConglobataCompletedNCT04161456Phase 2
• Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With ApremilastWithdrawnNCT04102449Phase 4
• Apremilast - Oral Lichen Planus TrialWithdrawnNCT03836885Phase 2
• Apremilast and Moderate to Severe Chronic Hand DermatitisWithdrawnNCT03741933Phase 4
• The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen PlanusActive, not recruitingNCT03656666Phase 2
• Apremilast as Anti-pruritic Treatment in Patients With Prurigo NodularisStatus unknownNCT03576287Phase 1/2
• Apremilast Treatment for Pruritus and Quality of Life in Scalp PsoriasisStatus unknownNCT03553433Phase 4

← Apremilast overview